 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- gresonitamab (AMG 910) / Amgen, Vyloy (zolbetuximab) / Astellas, AZD5863 / AstraZeneca
An anti-claudin 18.2/CD3 bispecific antibody for the treatment of claudin 18.2 positive gastric cancer (Section 3) - Mar 5, 2024 - Abstract #AACR2024AACR_9490;
However, Zolbetuximab (IMAB362) has successfully reached the Phase III end point, indicating positive clinical outcomes and establishing CLDN18.2 as a promising cellular and antibody therapeutic option. In conclusion, the novel anti-CLDN18.2
- ||| gresonitamab (AMG 910) / Amgen
Trial termination: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 24, 2024
P1, N=15, Terminated, Sponsor: Amgen
In conclusion, the novel anti-CLDN18.2 Completed --> Terminated; Business Decision
- || gresonitamab (AMG 910) / Amgen
Trial completion, Trial completion date, Trial primary completion date: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jun 6, 2022
P1, N=16, Completed, Sponsor: Amgen
Completed --> Terminated; Business Decision Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Jun 2022 | Trial primary completion date: Nov 2023 --> Jun 2022
- QLS31905 / Qilu Pharma
QLS31905, an anti-claudin 18.2/CD3 bispecific antibody for claudin 18.2-positive gastric cancer (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7074;
Overall, these data suggested that QLS31905 has similar efficacy to AMG 910 and is safer. QLS31905 may be an effective and clinically valuable treatment for patients with claudin 18.2-positive gastric cancer.
- || gresonitamab (AMG 910) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Dec 10, 2021
P1, N=16, Active, not recruiting, Sponsor: Amgen
QLS31905 may be an effective and clinically valuable treatment for patients with claudin 18.2-positive gastric cancer. N=70 --> 16 | Trial completion date: Oct 2025 --> Nov 2023 | Trial primary completion date: Oct 2025 --> Nov 2023 | Recruiting --> Active, not recruiting
- || gresonitamab (AMG 910) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 2, 2021
P1, N=70, Recruiting, Sponsor: Amgen
N=70 --> 16 | Trial completion date: Oct 2025 --> Nov 2023 | Trial primary completion date: Oct 2025 --> Nov 2023 | Recruiting --> Active, not recruiting Trial completion date: Jan 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
- || gresonitamab (AMG 910) / Amgen
Trial completion date, Trial primary completion date: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Nov 18, 2020
P1, N=70, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025 Trial completion date: Jun 2024 --> Aug 2025 | Trial primary completion date: Jun 2024 --> Aug 2025
- irinotecan / Generic mfg.
[VIRTUAL] Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2272;
P1
Funding: Amgen Inc. Clinical trial identification: NCT04260191 - Feb 7, 2020.
- ||| gresonitamab (AMG 910) / Amgen
Enrollment open: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 22, 2020
P1, N=70, Recruiting, Sponsor: Amgen
Clinical trial identification: NCT04260191 - Feb 7, 2020. Not yet recruiting --> Recruiting
- AMG 199 / Amgen, AMG 910 / Amgen
Preclinical evaluation of BiTE®immune therapy targeting MUC17 or CLDN18.2 for gastric cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3577;
In contrast, treatment with AMG 910 led to direct cell killing of CLDN18.2-expressing gastric mucosal cells in NHP, a finding which was fully reversible once treatment was stopped. AMG 199 and AMG 910 may offer the potential to improve outcomes in advanced gastric patients worldwide.
- ||| gresonitamab (AMG 910) / Amgen
New P1 trial: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Feb 6, 2020
P1, N=70, Not yet recruiting, Sponsor: Amgen
- | AMG 910 / Amgen, Alverix (amiloride hydrochloride) / Remedica
Journal: Mechanisms underlying the stimulatory effect of inhaled sulfur dioxide on vagal bronchopulmonary C-fibres. (Pubmed Central) - Jan 1, 2020
This conclusion was further supported by the results obtained from studies in isolated rat vagal bronchopulmonary sensory neurones and also in the cough response to SO inhalation challenge in awake mice. These results provide new insight into the underlying mechanism of harmful irritant effects in the respiratory tract caused by accidental exposure to high concentration of SO .